NeoCore Technology Co., Ltd AI Stock Analysis
NeoCore Technology Co., Ltd (4131) AI Stock Analysis
NeoCore Technology Co., Ltd
(TPEx:4131)
Moderate financials from revenue growth and balance sheet gains are offset by weak technicals in a downtrend and poor valuation due to losses.
NeoCore Technology Co., Ltd (4131) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- TWD 1.23B
- Dividend Yield
- ―
- Average Volume (3M)
- 18.34K
- Price to Earnings (P/E)
- -37.2
- Beta (1Y)
- 0.07
- Revenue Growth
- 42.88%
- EPS Growth
- -34.50%
- Country
- TW
- Employees
- 44
- Sector
- General
- Sector Strength
- 55
- Industry
- Biotechnology
NeoCore Technology Co., Ltd Business Overview & Revenue Model
Company Description
NeoCore Technology Co., Ltd. is primarily engaged in the creation, manufacture, and distribution of biochips and advanced rapid nucleic acid hybridization devices. Their extensive product range features systems designed for food safety screening, hum...
NeoCore Technology Co., Ltd Financial Statement Overview
Summary
Revenue grew 28.7% with gross margin at 35%, and balance sheet improved with debt-to-equity of 0.56, but ongoing net losses and negative cash flows limit the score.
Income Statement
68PositiveBalance Sheet
72PositiveCash Flow
42Neutral| Breakdown | TTM | Dec 2025 | Dec 2024 | Mar 2024 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 277.54M | 244.66M | 61.55M | 64.73M | 88.97M | 88.93M |
| Gross Profit | 110.17M | 86.45M | 3.29M | -9.09M | 11.78M | 19.40M |
| EBITDA | 3.62M | -33.41M | -43.89M | -72.11M | -29.49M | -15.11M |
| Net Income | -34.73M | -34.24M | -48.14M | -64.64M | -28.21M | -17.20M |
Balance Sheet | ||||||
| Total Assets | 581.03M | 549.84M | 340.76M | 548.75M | 266.79M | 281.96M |
| Cash, Cash Equivalents and Short-Term Investments | 76.27M | 114.51M | 207.99M | 299.29M | 46.26M | 39.87M |
| Total Debt | 186.04M | 158.66M | 24.46M | 96.89M | 114.08M | 96.69M |
| Total Liabilities | 274.16M | 248.84M | 35.67M | 197.47M | 185.81M | 164.60M |
| Stockholders Equity | 286.13M | 282.54M | 305.09M | 347.68M | 75.93M | 112.05M |
Cash Flow | ||||||
| Free Cash Flow | -82.25M | -26.30M | -69.66M | -75.42M | -3.43M | -17.15M |
| Operating Cash Flow | -38.54M | -20.67M | -57.15M | -63.88M | -2.69M | -17.15M |
| Investing Cash Flow | 18.81M | -63.21M | -25.17M | -11.69M | 5.51M | 2.50M |
| Financing Cash Flow | 53.43M | -9.61M | -2.97M | 328.60M | 27.06M | -3.44M |
NeoCore Technology Co., Ltd Peers Comparison
Overall Rating
TW:416161Neutral
TW:413151Neutral
TW:413348Neutral
TW:410945Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 61Neutral | TWD 1.22B | 11.45 | ― | 3.32% | 7.54% | 35.87% | |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| 51Neutral | TWD 1.21B | -37.17 | ― | ― | 42.88% | -34.50% | |
| 48Neutral | TWD 1.20B | 27.03 | ― | 0.56% | -4.19% | ― | |
| 45Neutral | TWD 1.21B | 256.25 | ― | 1.95% | 13.00% | 902.22% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TW:4131 | NeoCore Technology Co., Ltd | 30.65 | -2.00 | -6.13% | |
| TW:4109 | Jia Jie Biomedical Co., Ltd. | 10.25 | -5.51 | -34.96% | |
| TW:4133 | Abnova Taiwan Corp. | 20.00 | -3.47 | -14.79% | |
| TW:4161 | Bioptik Technology, Inc. | 21.10 | -4.50 | -17.57% | |
| TW:4195 | Genomics BioSci & Tech. Co., Ltd. | 14.90 | -10.05 | -40.28% | |
| TW:7803 | aetherAI Co., Ltd. | 12.50 | -20.15 | -61.72% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 09, 2026
